Skip to content

KEPHAS PHARMA

Active Private limited companyfounded 2022active for 4 yearsRue du Cheval Blanc 55, 6238 Pont-à-CellesKBO/BCE: BE 0793.326.574

Lifetime

2 annual accounts with figures on one time axis
peak of €30,726 in 2023
€13,925▼ 54.7%
peak of €23,160 in 2023
€7,346▼ 68.3%
peak of €33,505 in 2024
€33,505▲ 28.1%
€24,071▲ 16.7%
Board1 name since 2022
1 director
Documentsfilings and deeds
29-07-20252 days before the deadline
2024micro format
Gross margin from €30,726 to €13,925Result from €23,160 to €7,346Equity from €26,160 to €33,505Debts from €20,630 to €24,071Cash from €21,070 to €34,188

Key points

from the 2024 annual accounts

Turnover

≈ €150,000 estimated

The micro format states no turnover.

2025 accounts not filed, 114 days past the deadline

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 39,327 companies had the same profile as KEPHAS PHARMA has now. Each dot stands for 99 companies, two years later.

95.7%
were still trading
2.4%
stopped another way
1.8%
went bankrupt
  • Micro
  • 2 to 5 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 498,062 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.7% would go bankrupt within 24 months. In fact 1.8% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.4% 0.5%
3 0.6% 0.6%
4 0.7% 0.8%
5 0.9% 1.0%
6 1.4% 1.6%
7 1.7% 1.8%
8 1.9% 2.0%
9 3.1% 3.3%
10 5.9% 6.4%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 39,327 companies, not a prediction for KEPHAS PHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Managing director
  • founderdeed of 09-11-2022
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0793326574
Incorporation Founding capital of €3,000, 300 shares · Founded by · appointed as director and managing director and permanent representative · published on 09-11-2022 · Gazette deed
First establishment Rue du Cheval Blanc 55, Pont-à-Celles
All 5 events

Comparable companies

same main activity, similar in size and age
Company
KEPHAS PHARMA Pont-à-Celles €57,577 €13,925 58.2% -
ERAPHAR Haaltert €50,132 €16,957 78.1% -
Prometheus HealthCare Incourt €64,621 €11,987 23.6% -
APOTHEKER LAURA SPIRITUS Linter €62,639 €11,797 10.3% -
Katrien Smets Heist-op-den-Berg €56,328 €18,249 61.8% -
P.H.A. Anderlecht €60,047 €18,445 87.0% -
PHARMELLE Aalst €48,646 €13,408 21.4% -

These companies have the same main activity as KEPHAS PHARMA: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €48,600 and €64,600, founded between 2020 and 2023.

Official details

Source: KBO
Status
Active since 07-11-2022Normal situation
Activity
Retail sale of pharmaceutical productsNACE 47730and 2 others
Establishment unit
2.339.469.1606238 Pont-à-Celles, since 07-11-2022
Financial year end
31 December
Peppol
Reachable since 30-12-2025
Company details

Annual accounts 2024

€57,577▲ 23.1%
Filing
Filed on 29-07-2025
Financials

Insights on KEPHAS PHARMA

The 2024 annual accounts show equity of €33,505 and a net result of €7,346. Its solvency ranks better than 72% of 25,611 sector peers (NACE 47) in financial year 2024.

The company has been active since 2022 and the Belgian Official Gazette contains no insolvency or warning signals.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about KEPHAS PHARMA

What is the company number of KEPHAS PHARMA?
The company number of KEPHAS PHARMA is 0793.326.574. The VAT number is the same number with BE in front: BE 0793.326.574.
Where is KEPHAS PHARMA based?
The registered office is at Rue du Cheval Blanc 55, 6238 Pont-à-Celles.Company details
What does KEPHAS PHARMA do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of KEPHAS PHARMA?
KEPHAS PHARMA is a private limited company (BV).
When was KEPHAS PHARMA founded?
KEPHAS PHARMA was founded on 07-11-2022.
Is KEPHAS PHARMA still active?
Yes, KEPHAS PHARMA is an active enterprise in the KBO register.
What is the turnover of KEPHAS PHARMA?
The turnover in financial year 2024 is about €150,000. This figure is estimated from the gross margin of €13,925 and 137 comparable companies (NACE 477). It probably lies between €53,000 and €320,000. It is a rough estimate.Financials
Is KEPHAS PHARMA profitable?
In financial year 2024, KEPHAS PHARMA made a profit of €7,346.
Where can I find the annual accounts of KEPHAS PHARMA?
KEPHAS PHARMA filed 2 annual accounts with the National Bank of Belgium, the latest for financial year 2024.
When are the next annual accounts of KEPHAS PHARMA due?
KEPHAS PHARMA had to file the annual accounts for financial year 2025 by 31-07-2026. On 22-11-2026 they are not filed yet, 114 days past the deadline.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.